Assessment of drug-drug interactions: concepts and approaches

References

• AHONEN, J., DIKKOLA, K. T., SALMENPERA, M., HYNYNEN, M. and NEUVONEN, P. J., 1996, Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology, 85, 1246–1252.
   PubMedGoogle Scholar
• AZIE, N. E., BRATER, D. C., BECKER, P. A., JONES, D. R. and HALL, S. D., 1998, The interaction of diltiazem with lovastatin and pravastatin. Clinical Pharmacology and Therapeutics, 64, 369–377.
   PubMed Web of Science ®Google Scholar
• BACK, D. J., TJIA, J. F., KARBWANG, J. and COLBERT, J., 1998, In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British Journal of Clinical Pharmacology, 26, 23–29.
   Google Scholar
• BENSOUSSAN, C., DELAFORGE, M. and MANSUY, D., 1995, Particular ability of cytochrome P450 3A to form inhibitory P450—iron—metabolite complexes upon metabolic oxidation of aminodrugs. Biochemical Pharmacology, 49, 591–602.
   PubMed Web of Science ®Google Scholar
• BERNARD, S. A. and BRUERA, E., 2000, Drug interactions in palliative care. journal of Clinical Oncology, 18, 1780–1799.
   PubMedGoogle Scholar
• BOBERG, E., LIEM, A., MILLER, E. C. and MILLER, J. A., 1987, Inhibition by pentachlorophenol of the initiating and promoting activities of 1 -hydroysafrole for the formation of enzyme-altered foci and tumors in rat liver. Carcinogenesis, 8, 531–539.
   PubMedGoogle Scholar
• BOCK, K. W., FORSTER, A., GSCHAIDMEIER, H., BRUCK, M., MUNZEL, P., SCHARECK, W., FOURNEL-GIGLEUX, S. and BURCHELL, B., 1993, Paracetamol glucuronidation by recombinant rat and human phenol UDP-glycuronosyltransferases. Biochemical Pharmacology, 45, 1809–1 814.
   Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–331.
   PubMed Web of Science ®Google Scholar
• BRIAN, W. R., SARI, M. A., IWASAKI, M., SHIMADA, T., KAMINSKY, L. S. and GUENGERICH, F. P., 1990, Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry, 29, 11280–11292.
   PubMed Web of Science ®Google Scholar
• BURCHELL, B. and COUGHTRIE, M. W. H., 1989, UDP-glucuronosyltransferases. Pharmacology and Therapeutics, 43, 261–289.
   PubMed Web of Science ®Google Scholar
• BURCHELL, B., COUGHTRIE, M. W. H., JACKSON, M. R., SHEPHERD, S. R. P., HARDING, D. and HUME, R., 1987, Genetic deficiency of bilirubin glucuronidation in rats and humans. Molecular Aspects of Medicine, 9, 429–455.
   Google Scholar
• BUTLER, M. A., LANG, N. P., YOUNG, J. F., CAPORASO, N. E., VINEIS, P., HAYES, R. B., TEITEL, C. H., MASSENGILL, J. P., LAWSON, M. F. and KADLUBAR, F. F., 1992, Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 2, 116–127.
   PubMedGoogle Scholar
• CAMPBELL, N. R. C., VAN LOON, J. A., SUNDARAM, R. S., AMES, M. M., HANSCH, C. and WEINSHILBOUM, R., 1987, Human and rat liver phenol sulfotransferase structure—activity relationships for phenolic substrates. Molecular Pharmacology, 32, 813–819.
   Google Scholar
• CARLILE, D. J., HABOOZ, N., BAYLISS, M. K. and HOUSTON, J. B., 1999, Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. British Journal of Clinical Pharmacology, 47, 625–635.
   PubMed Web of Science ®Google Scholar
• CDER, 1997, Guidance for industry: drug metabolism/drug interactions in the drug development process: studies in vitro [http://www.fda.gov/cder].
   Google Scholar
• CDER, 1998, Guidance for industry: in vivo drug metabolism/drug interaction studies: study design, data analysis and recommendations for dosing and labelling [http://wwwfda.gov/cder].
   Google Scholar
• CHANG, T. K. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437–442.
   Google Scholar
• Cmu, L. S. H. and HUSKEY, S. E. W., 1998, Aspect n-glucuronidation of xenobiotics symposium. Species differences in n-glucuronidation. Drug Metabolism and Disposition, 26, 838–847.
   Google Scholar
• CLARK, S. E., 1998, In vitro assessment of human cytochrome P450. Xenobiotica, 28, 1167–1202.
   PubMedGoogle Scholar
• CONNEY, A., 1982, Induction of microsomal enzymes by foreign chemicals and carcinogensis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. Cancer Research, 42, 4875–4917.
   PubMed Web of Science ®Google Scholar
• CPMP, 1998, Note for guidance on the investigation of drug interactions, EWP/560/95 [http:// www.eudra.org/emea.html].
   Google Scholar
• DIAZ, D., FABRE, I., DAUJAT, M., SAINTAUBERT, B., BORIES, P., MICHEL, H. and MAUREL, P., 1990, Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology, 99, 737–747.
   PubMed Web of Science ®Google Scholar
• DICKINS, M., ELCOMBE, C. R., MALONEY, S. J., NETTER, K. J. and BRIDGES J. W., 1979, Further studies on the dissociation of the isosafrole metabolite—cytochrome P450 complex. Biochemical Pharmacology, 28, 231–238.
   Google Scholar
• DONATO, M. T., CASTELL, J. V. and GOMEZ-LECHON, M. J., 1995, Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metabolism Disposition, 23, 553–558.
   Google Scholar
• EAGLING, V. A., TJIA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
   PubMed Web of Science ®Google Scholar
• EBERTS, F. S., PHILOPOULOS, Y., REINEKE, L. M. and VLIEK, R. W., 1981, Triazolam disposition. Clinical Pharmacology and Therapeutics, 29, 81–93.
   PubMed Web of Science ®Google Scholar
• EDWARDS, R. J., 1998, Targeting anti-peptide antibodies towards P450 enzymes. In I. R. Phillips and E. A. Shepard (eds), Cytochrome P450 Protocols (Humana Press Inc.).
   Google Scholar
• EL-SANKARY, W., PLANT, N. J., GIBSON, G. G. and MOORE, D. J., 2000, Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metabolism and Disposition, 28, 493–496.
   Google Scholar
• FISCHER, U., ROHDE, B., WACKE, R., STANGE, J., NITSCHKE, F. P., ADAM, U. and DREWELOW, B., 1997, Prediction of in vivo drug interaction from in vitro systems exemplified by interaction between verapamil and cimetidine using human liver microsomes and primary hepatocytes. Journal of Clinical Pharmacology, 37, 1150–1159.
   PubMedGoogle Scholar
• FISHER., M. B., VANDENBRANDEN, M., FINDLAY, K., BURCHELL, B., THUMMEL, K. E., HALL, S. D. and WRIGHTON, S. A., 2000, Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics, 10, 727–739.
   Google Scholar
• FRYE, R. F., MATZKE, G. R., ADEDOYIN, A., PORTER, J. A. and BRANCH, R. A., 1997, Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes. Pharmacokinetics and Drug Disposition, 62, 365–376.
   Google Scholar
• FURLONG, B. B., WEAVER, R. P. and GOLDSTEIN, J. A., 1987, Covalent binding to DNA mutagenicity of 2,4-diaminotoluene metabolites produced by isolated hepatocytes and 9000g supernatant from Fischer 344 rats. Carcinogenesis, 8, 247–251.
   PubMed Web of Science ®Google Scholar
• GIBBS, M. A., KUNZE, K. L., HOWALD, W. N. and THUMMEL, K. E., 1999, Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metabolism and Disposition, 27, 596–599.
   PubMed Web of Science ®Google Scholar
• GIDDINGS S. J., CLARKE, S. E. and GIBSON, G. G., 1997, CYP4A1 gene transfection studies and the peroxisome proliferator-activated receptor: development of a high-throughput assay to detect peroxisome proliferators. European Journal of Drug Metabolism and Pharmacokinetics, 22, 315–319.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEM, B. I., 1994a, Evidence that CYP2C19 is the major (s)-mephenytoin 4'-hydroxylase in humans. Biochemistry, 33, 1743–1752.
   Google Scholar
• GOLOVINSKY, E., NAYDENOVA, Z. and GRANCHAROV, K., 1998, UDP-glucuronosyltransferase inhibitors. European Journal of Drug Metabolism and Pharmacokinetics, 23, 453–456.
   PubMedGoogle Scholar
• GORSKI, J. C., JONES, D. R., HAECHNER-DANIELS, B. D., HAMMAN, M. A., O'MARA, JR, E. M. and HALL, S. D., 1998, The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clinical Pharmacology and Therapeutics, 64, 133–143.
   Google Scholar
• GRANNEMAN, G. R., BRAECKMAN, R. A., LOCKE, C. S., CAVANAUGH, J. H., DUBE, L. M. and AWNI, W. M., 1995, Effect of zileuton on theophylline pharmacokinetics Clinical Pharmacokinetics, 29, 77–83.
   Google Scholar
• GRANT, D. M., BLum, M., BEER, M. and MEYER, U. A., 1991, Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Molecular Pharmacology, 39, 184–191.
   PubMed Web of Science ®Google Scholar
• GREEN, M. D., KING, C. D., MOJARRABI, B., MACKENZIE, P. I. and TEPHLY, T. R., 1998, Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metabolism and Disposition, 26, 507–512.
   PubMed Web of Science ®Google Scholar
• GREENBLATT', D. J., VON MOLTE, L. L., HARMATZ, J. S. and SHADER, R. I., 1999, Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. Journal of Clinical Psychopharmacology, 19, 23s–35s.
   Google Scholar
• GROTHUSEN, A., HARDT, J., BRAUTIGAM, L., LANG, D. and BROKER R., 1996, A convenient method to discriminate between cytochrome P450 enzymes and fiavin-containing monooxygenases in human liver microsomes. Archives of Toxicology, 71, 64–71.
   Google Scholar
• GUENGERICH, F. P., 1988, Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Molecular Pharmacology, 33, 500–508.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1990, Mechanism-based inactivation of human liver mictosomal cytochrome P450 IIIA4 by gestodene. Chemical Research and Toxicology, 3, 363–371.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1996, In vitro techniques for studying drug metabolism. Journal of Pharmacokinetks and Biopharmaceutics, 24, 521–533.
   PubMedGoogle Scholar
• GUENGERICH, F. P., Kim, D. H. and IwasAKI, M., 1991, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research and Toxicology, 4, 168–179.
   PubMed Web of Science ®Google Scholar
• HALPERT, P, 1981, Covalent modification of lysine during the suicide inactivation of rat liver cytochrome P-450 by chloramphenicol. Biochemical Pharmacology, 30, 875–881.
   PubMed Web of Science ®Google Scholar
• HEATH, E. C. and DINGELL, J. V., 1974, The interaction of foreign chemical compounds with the glucutonidation of estrogens in vitro. Drug Metabolism and Disposition, 2, 556–565.
   PubMed Web of Science ®Google Scholar
• HEIN, D. W., 1988, Acetylator genotype and arylamine-induced carcinogenesis. Biochimka et Biophyska Acta, 948, 37–66.
   PubMed Web of Science ®Google Scholar
• HICKMAN, D., WANG, J.P., WANG, Y. and UNADKAT, J. D., 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metabolism and Disposition, 26, 207–215.
   PubMed Web of Science ®Google Scholar
• HONIG, P. K., WORTHAM, D. C., ZAMANI, K., CONNER, D. P., MULLIN, J. C. and CANTILENA, L. R., 1993, Terfenadine—ketoconazole interaction: pharmacokinetics and electrocardiographic consequences. Journal of the American Medical Association, 269, 1513–1518.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469–1474.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B. and KENWORTHY, K. E., 2000, In vitro—in vivo scaling of CYP kinetic data not consistent with the classical Michaelis—Menten model. Drug Metabolism and Disposition, 28, 246–254.
   PubMed Web of Science ®Google Scholar
• HUMPHREY, M. J., JEvoNs, S. and TARBIT, M. H., 1985, Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrobial Agents and Chemotherapy, 28, 648–653.
   PubMed Web of Science ®Google Scholar
• HUNT, C. M., WATKINS, P. G., SAENGER, P., STAVE, G. M., BARLASCINI, N., 1992, Heterogeneity of CYP3A isoforms metabolising erythromycin and cortisol. Clinical Pharmacology and Therapeutics, 51, 1 8–23.
   Google Scholar
• HURWITZ, A., VACEK, J. L., BOTTERON, G. W., SZTERN, M. I., HUGHES, E. M. and JAYARAJ, A., 1991, Mexiletine effects on theophylline disposition. Clinical Pharmacology and Therapeutics, 50, 299–307.
   PubMed Web of Science ®Google Scholar
• ITO, K., IWATSUBO, T., KANAMITSU, S., NAKAJIMA, Y. and SUGIYAMA, Y., 1998, Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annual Review of Pharmacology and Toxicology, 38, 461–499.
   PubMed Web of Science ®Google Scholar
• ITO, K., KUSUHARA, H. and SUGIYYAMA, Y., 1999, Effects of intestinal CYP3A4 and p-glycoprotein on oral drug absorption-theoretical approach. Pharmaceutical Research, 16, 225–231.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., HIROTA, N., OOIE, T., SUZUKI, H., SHIMANDA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147–171.
   PubMed Web of Science ®Google Scholar
• JANKEL, C. A. and FrrrERmAN, L. K., 1993, Epidemiology of drug—drug interactions as a cause of hospital admissions. Drug Safety, 9, 51–59.
   PubMed Web of Science ®Google Scholar
• JOHNSON, M. D., NEWKIRK, G. and WHITE, J. R., 1999, Clinically significant drug interactions. Postgraduate Medicine, Drug Interactions, 105, 193–222.
   PubMed Web of Science ®Google Scholar
• JONEN, H. G., HUTHWOHL, B., Kum, R. and Kum, G. F., 1974, Influences of pyridine and some pyridine derivatives on spectral properties of reduced microsomes and on mictosomal drug metabolizing activity. Biochemical Pharmacology, 23, 1319–1329.
   PubMed Web of Science ®Google Scholar
• JUNG, F., RICHARDSON, T. H., ItAucv, J. L. and JOHNSON, E. F., 1997, Diazepam metabolism by cDNA-expressed human 2C P450s identification of P4502C18 and P4502C19 as low Km diazepam N-demethylases. Drug Metabolism and Disposition, 25, 133–139.
   PubMed Web of Science ®Google Scholar
• JuRiniA-RomEr, M., HUANG, H. S., BECK, D. J. and Li, A. P., 1996, Evaluation of drug interactions in intact hepatocytes: inhibitors of terfenadine metabolism. Toxicology In Vitro, 10, 655–663.
   Google Scholar
• KANAMITSU, S., ITO, K. and SUGIYAMA, Y., 2000, Quantitiative prediction of in vivo drug—drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentrations of inhibitor at the inlet to the liver. Pharmaceutical Research, 17, 2000.
   Google Scholar
• KENWORTHY, K. E., BLOOMER, J. C., CLARKE, S. E. and HOUSTON, J. B., 1999, CYP3A4 Drug interactions: correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology, 48, 716–727.
   PubMed Web of Science ®Google Scholar
• KINIRONS, M. T., O'SHEA, D., DOWNING, T. E., FITZWILLIAM, A. T., JOELLENBECK, L., GROOPMAN, J. D., WILKINSON, G. R. and WOOD, A. J. J., 1993, Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clinical Pharmacology and Therapeutics, 54, 621–629.
   Google Scholar
• KINIRONS, M. T., O'SHEA, D., GROOPMAN, J. D., THUMMEL, K. E., WOOD, A. J. and WILKINSON, J. R., 1994, Route of administration does not explain the lack of correlation between putative in vivo probes of cytochrome P4503A. British Journal of Clinical Pharmacology, 37, 501P.
   Google Scholar
• KOHL, C. and STEINKELLNER, M., 2000, Prediction of pharmacokinetic drug/drug interactions from in vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicarn with oral anticoagulants. Drug Metabolism and Disposition, 28, 161–168.
   PubMed Web of Science ®Google Scholar
• KOLARS, J. C., SCHMIEDLIN-REN, P., SCHUETZ, J. D., FANG, C. and WATKINS, P. B., 1992, Identification of rifampin-inducible P450111A4 (CYP3A4) in human bowl enterocytes. Journal of Clinical Investigations, 90, 1871–1878.
   Google Scholar
• KOMATSU, K., ITo, K., NAKAJIMA, Y., KANAMITSU, S.I., IMAOKA, S., FUNAE, Y., GREEN, C. E., TYSON, C. A., SHIMADA, N. and SUGIYAMA, Y., Prediction of in vivo drug—drug interactions between tolbutamide and various sulfonamides in human based on in vitro experiments. Drug Metabolism and Disposition, 28, 475–481.
   Google Scholar
• KORZEKWA, K. R., KRISHNAMACHARY, N., SHOU, M., OGAI, A., PARISE, R. A., RETTIE, A. E., GONZALEZ, F. J. and TRACY, T. S., 1998, Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 37, 4137–4147.
   PubMed Web of Science ®Google Scholar
• KOSTER, H., HALSEMA, I., SCHOLTENS, E., MEERMAN, J. H. N., PANG, K. S. and MULDER, G. J., 1982, Selective inhibition of sulfate conjugation in the rat: pharmacokinetics and characterization of the inhibitory effect of 2,6-chloro-4-nitrophenol. Biochemical Pharmacology, 31, 1919–1 924.
   Google Scholar
• KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, Oxidation of midazolam and triazolarn by human liver cytochrome P450 3A4. Molecular Pharmacology, 36, 89–96.
   PubMed Web of Science ®Google Scholar
• KUMAR, K. and BALLANTYNE, J., 2000, Use of general regression neural networks for determination of inhibitor/inducer activity of coadministered agents. AAPS, abst 3549.
   Google Scholar
• KUPFER, A., SCHMID, B., PREISIG, R. and PFA, G., 1984b, Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet, ii, 517–518.
   Google Scholar
• LANG, D. H., YEUNG, C. K., IBARRA, PETER, R. M., GASSER, R., ITAGAKI, K., PHILPOT, R. M. and RETTIE, A. E., 1998, Isoforrn specificity of trimethylamine N-oxygenation by human flavin- containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FM03. Biochemical Pharmacology, 56, 1005–1012.
   Google Scholar
• LASKER, J. M., WESTER, M. R., ÄRAMSOMBATDEE, E. and RAUCY, J. L., 1998, Characterization of CYP2C9 from human liver: respective roles in microsomal tolbutamide, s-mephenytoin, and omeprazole hydroxylations. Archives of Biochemistry and Biophysics, 353, 16–28.
   Google Scholar
• LAWTON, M. P., CASHMAN, J. R., CRESTEIL, T., DOLPHIN, C. T., ELFARRA, A. A., HINES, R. N., HODGSON, E., KIMURA, T., OZOLS, J., PHILLIPS, I. R., PHILPOT, R. M., POULSEN, L. L., RETTIE, A. E., SHEPARD, E. A., WILLIAMS, D. E. and ZIELGER, D. M., 1994, A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Archives of Biochemistry and Biophysics, 308, 254–257.
   PubMed Web of Science ®Google Scholar
• LE BIGOT, J. F., CRESTEIL, T., KIECHEL, J. R. and BEAUNE, P., 1983, Metabolism of ketotifen by human liver microsomes. In vitro characterization of a tertiary ammonium glucuronide. Drug Metabolism and Disposition, 11, 585–589.
   PubMedGoogle Scholar
• LE, J. H. and DOUGALL, I. G., 1993, Further concerns over Cheng—Prusoff analysis. Trends in Pharmacological Sciences, 14, 110–112.
   PubMedGoogle Scholar
• LEHMAN, J. P., FENSELAU, C. and DEPAULO, J. R., 1983, Quaternary ammonium-linked glucuronides of amitriptyline, imipramine and chlorpromazine. Drug Metabolism and Disposition, 11, 221–225.
   Google Scholar
• LESCA, P., RADINARIVO, E., LESCOINTE, P. and MANSUY, D., 1979, A class of strong inhibitors of microsomal monooxygenases: the ellipticines. Chemko-Biological Interactions, 24, 189–197.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., 1996a, P450 substrate specificity and metabolism. In Cytochromes P450: Structure, Function and Mechanism (London: Taylor & Francis), pp. 115–167.
   Google Scholar
• LEWIS, D. F. V., 1996b, Induction, regulation and inhibition. In Cytochromes P450: Structure, Function and Mechanism (London: Taylor & Francis), pp. 169–208.
   Google Scholar
• LI, L. I., MAUREL, P., GOMEZ-LECHON, M. J., CHENG, L. C. and JunntA-RomET, M., 1997, Preclinical evaluation of drug—drug interaction potential: present status of the implication of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chemico-Biological Interactions, 107, 5–16.
   Google Scholar
• LIN, J. H. and Lu, A. Y. H., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetk, 35, 361–390.
   Google Scholar
• LOWN, K. S., THUMMEL, K. E., BENEDICT, P. E., SHEN, D. D., TURGEON, D. K., BERENT, S. and WATKINS, P. B., 1995, The erythromycin breath test predicts the clearance of midazolam. Clinical Pharmacology and Therapeutics, 57, 16–24.
   PubMed Web of Science ®Google Scholar
• LU, A. Y., 1998, Drug-metabolism research challenges in the new millennium. Individual variability in drug therapy and drug safety. Drug Metabolism and Disposition, 26, 1217–1222.
   PubMed Web of Science ®Google Scholar
• MACHINIST, J. M., MAYER, M. D., SHET, M. S., FERRERO, J. L. and RODRIGUES, A. D., 1995, Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its n-dehydroxylated metabolite, abbott-66193. Drug Metabolism and Disposition, 23, 1163–1174.
   PubMed Web of Science ®Google Scholar
• MACKENZIE, P. I., OWENS, I. S., BURCHELL, B., BOCK, K. W., BAIROCH, A., BELANGER, A., FOURNEL-GIGLEUX, S., GREEN, M., Hum, D. W., IYANAGI, T., LANCET, D., LOUISOT, P., MAGDALOU, J., CHOWDHURY, J. R., RITTER, J. K., SCHACHTER, H., TEPHLY, T. R., TIPTON, K. F. and NEBERT, D. W., 1997, The UDP-glycosyltransferaw gene super family: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7, 255–269.
   Google Scholar
• MADANI, S., PAINE, M. F., LEWIS, L., THUMMEL, K. E. and SHEN, D. D., 1999, Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharmaceutical Research, 16, 1199–1205.
   PubMed Web of Science ®Google Scholar
• MAGDALOU, J., HERBER, R., BIDAULT, R. and SIEST, G., 1992, In vitro n-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 260, 1166–1173.
   PubMed Web of Science ®Google Scholar
• MALATY, L. I. and KUPER, J. J., 1999, Drug Interactions of HIV protease inhibitors. Drug Safety, 20, 147–169.
   PubMed Web of Science ®Google Scholar
• MARROUM, P. L., UPPOOR, R. S., PARMELLE, T., AJAYI, F., BURNETT, A., Yu, R., SVADJIAN, R., LESKO, L. J. and BALIAN, J. D., 2000, In vivo drug-drug interaction studies - a survey of all new molecular entities approved from 1987 to 1997. Clinical Pharmacology and Therapeutics, 68, 280–285.
   PubMed Web of Science ®Google Scholar
• MATSUI, M. and HOMMA, H., 1994, Biochemistry and molecular biology of drug-metabolizing sulfotransferase. International Journal of Biochemistry, 26, 1237–1247.
   PubMedGoogle Scholar
• MAURER, T. S., TABRIZI-FARD, M. A. and FUNG, H., 2000, Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery. Journal of Pharmaceutical Sciences, 89, 1404–1414.
   Google Scholar
• MAURICE, M., PICHARD, L., DAUJAT, M., FABRE, I., JoyEux, H., DOMERGUE, J. and MAUREL, P., 1992, Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASAB Journal, 6, 752–758.
   PubMed Web of Science ®Google Scholar
• MAYHEW, B. S., JONES, D. R. and HALL, S. D., 2000, An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition, 28, 1031–1037.
   PubMed Web of Science ®Google Scholar
• MCDONNELL, W. M., HITOMI, E. and Asitmu, F. K., 1996, Identification of bilirubin UDP-GTs in the human alimentary tract in accordance with the gut as a putative metabolic organ. Biochemical Pharmacology, 51, 483–488.
   PubMed Web of Science ®Google Scholar
• MCGINNITY, D. F., PARKER, A. J., SOARS, M. and RILEY, R. J., 2000, Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition, 28, 1327–1334.
   PubMed Web of Science ®Google Scholar
• McLuaE, J. A., MINERS, J. O. and BIRKETT, D. J., 2000, Nonspecific binding of drugs to human liver microsomes. British Journal of Clinical Pharmacology, 49, 453–461.
   PubMedGoogle Scholar
• MEERMAN, J. H. N., STERENBORG, H. M. J. and MULDER, G. J., 1983, Use of pentachlorophenol as long-term inhibitor of sulfation of phenols and hydroxamic acids in the rat in vivo. Biochemical Pharmacology, 32, 1587–1593.
   Google Scholar
• MEIJER, D. K. F., HOOIVELD, G. J. E. J., SCHINKEL, A. H., VAN MONTFOORT, J. E., HAAS, M., DE ZEEUW, D., MOOLENAAR, F., SMIT, J. W. and MEIER, P. J., 1999, Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery. Nephrology Dialysis Transplantation, 14 (suppl. 4), 1–3.
   PubMedGoogle Scholar
• MEREDITH, C. G., MALDONADO, A. L. and SPEEG, K. V., 1985, The effect of ketoconazole OII hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metabolism and Disposition, 13, 156–162.
   PubMed Web of Science ®Google Scholar
• MERRY, C., MULCHAHY, F., BARRY, M., GIBBONS, S. and BACK, D., 1997, Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease-inhibitors for patients with HIV-disease. AIDS, 11, 268–269.
   PubMed Web of Science ®Google Scholar
• MINERS, J. O. and BIRKETT, D. J., 1996, The use of caffeine as a metabolic probe for human drug metabolizing enzymes. General Pharmacology, 2, 245–249.
   Google Scholar
• MINERS, J. O. and BIRKETT, D. J., 1998, Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology, 45, 525–538.
   PubMed Web of Science ®Google Scholar
• MISTRY, M. and HOUSTON, J. B., 1987, Glucuronidation in vitro and in vivo: comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metabolism Disposition, 15, 710–717.
   PubMed Web of Science ®Google Scholar
• MIYAUCHI, S., SAWADA, Y., IGA, T., HANANO, M. and SUGIYAMA, Y., 1993, Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharmaceutical Research, 10, 434–440.
   PubMed Web of Science ®Google Scholar
• MOLDEUS, P., ANDERSON, B. and GERGELY, V., 1979, Regulation of glucuronidation and sulphate conjugation in isolated hepatocytes. Drug Metabolism and Disposition, 7, 416–419.
   PubMed Web of Science ®Google Scholar
• MORTIMER, O., LINDSTROM, B., LAURELL, H., BERGMAN, U. and RANE, A., Dextromethorphan: polymorphic serum patterns of the O-demethylated and didemethylated metabolites in man. British Journal of Clinical Pharmacology, 27, 223–227.
   Google Scholar
• MULDER, G. J., 1990, Competition between Conjugations for the Same Substrate. In G. J. Mulder (ed.), Conjugation reactions in drug metabolism (London: Taylor & Francis), pp. 41–49.
   Google Scholar
• MULDER, G. J., COUGHTRIE, M. W. H. and BURCHELL, B., 1990, Glucuronidation. In G. J. Mulder (ed.), Conjugation Reactions in Drug Metabolism (London: Taylor & Francis), pp. 51–105.
   Google Scholar
• MULDER, G. J. and JAKOBY, W. B., 1990, Sulfation. In G. J. Mulder (ed.), Competition Between Conjugations for the Same Substrate (London: Taylor & Francis), pp. 107–161.
   Google Scholar
• MURRAY, M., 1988, Complexation of cytochrome P450 isozymes in hepatic microsomes from SKF 525-A-induced rats. Archives of Biochemistry and Biophysics, 262, 381–388.
   PubMed Web of Science ®Google Scholar
• MURRAY, M., 1992, P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clinical Pharmacokinetk Concepts, 23, 132–146.
   PubMed Web of Science ®Google Scholar
• NAKAMURA, H., SAMO, H., YAMAZAKI, M. and SUGIYAMA, Y., 1994, Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. Journal of Pharmacology and Experimental Therapeutics, 269, 1220–1226.
   PubMedGoogle Scholar
• NARIMATSU, S. YAmAmom, S., KATO, R., MASUBUCHI, Y. and HORI, T., 1999, Contribution of fiavin-containing monooxygenase and cytochrome P450 to imipramine N-oxidation in rat hepatic microsomes. Biological and Pharmaceutical Bulletin, 22, 567–571.
   Google Scholar
• NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, F. J., GUNSALUS, I. C., GOTOH, O., OKUDA, K. and NEBERT, D. W., 1993, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA and Cell Biology, 12, 1–51.
   PubMed Web of Science ®Google Scholar
• NESTOROV, I., AARONS, L. J. and ROWLAND, M., 1998a, Lumping of whole body physiologically based pharmacokinetic models. Journal of Pharmacokinetics and Biopharmaceutks, 26, 21–46.
   PubMedGoogle Scholar
• NESTOROV, I., AARONS, L. J. and ROWLAND, M., 1998b, Quantitative structure-pharmacokinetic relationships. II. Mechanistically based model for the relationship between the tissue distribution parameters and the lipophilicity of the compounds. Journal of Pharmacokinetics and Biopharmaceutics, 26, 521–545.
   PubMedGoogle Scholar
• NESTOROV, I., CARLILE, D., JONES, H., HOUSTON, J. B. and ROWLAND, M., 2000, Incorporating variability and uncertainty into the in vitro-in vivo prediction of hepatic clearance. In IFAC Symposium: Modelling and Control in Biomedical Systems, Greifswald, Germany, pp. 109–114.
   Google Scholar
• NESTOROV, I., PETROV, I., HADJITODOROV, S. and ROWLAND M., 1999, Empirical versus mechanistic modelling: comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetics relationship. Pharmaceutical Sciences, 1, article 17.
   Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• NGUI, J. S., TANG, W., STEARNS, R. A., SHOU, M., MILLER, R. R., ZHANG, Y., LIN, J. H. and BAILLIE, T. A., 2000, Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metabolism and Disposition, 28, 1043–1050.
   PubMed Web of Science ®Google Scholar
• OBAcit, R. S., 1997, Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metabolism and Disposition, 25, 1359–1369.
   PubMedGoogle Scholar
• OBACH, R. S., BAXTER, J. G., LISTON, T. E., SILBER, B. A., JONES, B. C., MACINTYRE, F., RANCE, D. J. and WASTALL, P., 1997, The prediction of human pharmacokinetics parameters from preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental Therapeutics, 283, 46–58.
   PubMed Web of Science ®Google Scholar
• OGG, M. S., GRAY, T. J. B. and GIBSON, G. G., 1997, Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene. European Journal of Drug Metabolism and Pharmacokinetics, 22, 311–313.
   Google Scholar
• OGG, M. S., WILLIAMS, J. M., TAaarrr, M., GOLDFARB, P. S., GRAY, T. J. B. and GIBSON, G. G., 1999, A reporter gene assay to assess the molecular mechanisms of xenobiotic- dependent induction of the human CYP3A4 gene in vitro. Xenobiotica, 29, 269–279.
   Google Scholar
• OIKKOLA, K. T., ARANKO, K., LUURILA, H., HILLER, A., SAARNIVAARA, L., HIMBERG, J. J. and NEUVONEN, P. J., 1993, A potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics, 53, 298–305.
   PubMedGoogle Scholar
• ONG, CE., COULTER, S., BIRKETT, D. J., BHASKER, C. R. and MINERS, J. O., 2000, The xenobiotic inhibitor profile of cytochrome P4502C8. British Journal of Clinical Pharmacology, 50, 573–580.
   PubMedGoogle Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T. and GONZALEZ, F. J., 1996, Specificity of substrate and inhibitor probes for cytochrome P45 Os: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• ORTIZ DE MONTELLANO, O., 1988, Suicide inhibitors for drug metabolising enzymes: mechanisms and biological consequences. In Progress in Drug Metabolism, vol. 11 (New York: Taylor & Francis), pp. 99–148.
   Google Scholar
• PAINE, M. F., SCHMIEDLIN-REN, P. and WATKINS, P. B., 1999, Cytochrome P-450 1A1 expression in human small bowl: interindividual variation and inhibition by ketoconazole. Drug Metabolism and Disposition, 27, 360–364.
   Google Scholar
• PANG, K. S., 1990, Kinetics of conjugation reactions in eliminating organs. In G. J. Mulder (ed.), Competition between Conjugations for the Same Substrate (London: Taylor & Francis), pp. 5–39.
   Google Scholar
• PANG, K. S. and CHIBA, M., 1994, Metabolism: scaling-up from in vitro to organ and whole body. In P. G. Welling and L. P. Balaut (eds), Handbook of Experimental Pharmacology (New York: Springer-Verlag), pp. 101–187.
   Google Scholar
• PARK, B. K., KITTERINGHAM, N. R., PIRMOHAMED, M. and TUCKER, G. T., 1996, Relevance of induction of human drug-metabolising enzymes: pharmacological and toxicological implications. British Journal of Clinical Pharmacology, 41, 477–491.
   PubMed Web of Science ®Google Scholar
• PARK, CS., CHUNG, W.G., KANG, J.H., Ron, H.K., LEE, K.H. and CHA, Y.N., 1999, Phenotyping of fiavin-containing monooxydenase using caffeine metabolism and genotyping of FM03 gene in a Korean population. Pharmacogenetics, 9, 155–164.
   PubMedGoogle Scholar
• PARKINSON, A., 1996a, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicology Pathology, 24, 45–57.
   Web of Science ®Google Scholar
• PARKINSON, A., 1996b, Biotransformation of xenobiotics. In C. D. Klassen, M. O. Arndur and J. Doull (eds), CasarettDoull's Toxicology: The Basic Science of Poisons (New York: McGraw-Hill),pp. 113–186.
   Google Scholar
• PASCUSSI, J.M., GERBAL-CHALOIN, S., FABRE, J.-M., MAUREL, P. and VILAREM, M.-J., 2000, Dexamethazone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Molecular Pharmacology, 58, 1441–1450.
   Google Scholar
• PESSAYRE, D., DESCATOIRE, V., TINEL, M. and LARREY, D., 1982, Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P450. Comparison with troleandomycin. Journal of Pharmacology and Experimental Therapeutics, 221, 215–221.
   PubMed Web of Science ®Google Scholar
• PITCHARD, L., FABRE, I., FABRE, G., DOMERGUE, J., SAINT-AUBERT, B., MOURAD, G. and MAUREL, P., 1990, Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver micro somes. Drug Metabolism and Disposition, 18, 595–606.
   Google Scholar
• PORTER, S. J., SOMOGYI, A. A. and WHITE, J. M., 2000, Kinetics and inhibition of the formation of 6(-naltrexol from naltrexone in human liver cytosol. British Journal of Clinical Pharmacology, 50, 465A–71.
   Google Scholar
• RE, A., SAWE, J., LINDBERG, B., VENSSON, J. O., GARLE, M., ERWALD, R. and JORULF, H., 1984, Morphine glucuronidation in the rhesus monkey: a comparative in vivo and in vitro study. Journal of Pharmacology and Therapeutics, 229, 571–576.
   PubMedGoogle Scholar
• RENDIC, S. and DI CARLO, F. J., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews, 29, 413–580.
   PubMed Web of Science ®Google Scholar
• RETTIE, A. E. and LANG, D. H., 2000, Can caffeine metabolism be used as an in-vivo probe for human fiavin-containing monooxgenase activity. Pharmacogenetics, 10, 275–277.
   PubMedGoogle Scholar
• RODRIGUES A. D. and WONG, S. L., 1997, Application of human liver microsomes in metabolism-based drug—drug interactions: in vitro—in vivo correlations and the Abbott Laboratories experience. Advances in Pharmacology, 43, 65–101.
   PubMedGoogle Scholar
• ROGERSON, T. D., WILKINSON, C. F. and HETARSKI, K., 1977, Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes. Biochemical Pharmacology, 26, 1 O39–1042.
   Google Scholar
• Roos, T. C. and MERK, H. F., 2000, Important drug interactions in dermatology. Drugs, 59, 181–192.
   PubMedGoogle Scholar
• ROWLAND, M. and MATIN, S. B., 1973, Kinetics of drug interactions. Journal of Pharmacokinetics and Biopharmaceutics, 1, 553–567.
   Google Scholar
• SADEQUE, A. J., EDDY, A. C., NEIER, G. P. and RETTIE, A. E., 1992, Stereoselective sulfoxidation by human fiavin- containing monooxygenase: evidence for catalytic diversity between hepatic, renal and fetal forms. Drug Metabolism and Disposition, 20, 832–839.
   PubMed Web of Science ®Google Scholar
• SATon, T., MATSUI, M. and TAMURA, HO., 2000, Sulfotransferases in a human colon carcinoma cell, caco-2. Biological and Pharmaceutical Bulletin, 27, 810–814.
   Google Scholar
• SCHMIDER, J., GREENBLATT, D. J., HARMATZ, J. S. and SHADER, R. I., 1996, Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. British Journal of Clinical Pharmacology, 41, 593–604.
   PubMed Web of Science ®Google Scholar
• SEGAL, I. H., 1993, Enzyme Kinetics, Behaviour and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (New York: Wiley).
   Google Scholar
• SHARP, S., MAK, L. Y., SMITH, D. J. and COUGHTRIE, M. W. H., 1992, Inhibition of human and rabbit liver steroid and xenobiotic UDP-glucuronosyltransferases by tertiary amine drugs — implications for adverse drug reactions. Xenobiotica, 22, 13–25.
   PubMed Web of Science ®Google Scholar
• SHAW, P. M., BARNES, T. S., CAMERON, D., ENGEST, J., MELVIN, W. T., OMAR, G., PETRIE, J. C., RUSH, W. R., SNYDER, C. P., WHITING, P. H., WOLF, C. R. and BURKE, M. D., Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism. Biochemical Journal, 263, 653–663.
   Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, P., 1994, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SILVERMAN R. B., 1988, Criteria for mechanism-based enzyme inactivation. In Mechanism-based Enzyme Inactivation: Chemistry and Enzymology (Boca Raton: CRC Press), pp. 3–27.
   Google Scholar
• SINZ, M. W. and REMMEL, R. P., 1991, Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metababolism and Disposition, 19, 149–153.
   PubMed Web of Science ®Google Scholar
• SPIELBERG, S. P., 1996, N-acetyltransferases pharmacogenetics and clinical consequences of polymorphic drug metabolism. Journal of Pharmacokinetks and Biopharmaceutks, 24, 509–519.
   PubMedGoogle Scholar
• SPINA, E., Grrro., C., AVENOSO, A., CAMPO, G. M., CARurri, A. P. and PERUCCA, E., 1997, Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. European Journal of Clinical Pharmacology, 51, 395–398.
   Google Scholar
• STEVENS, G. J., PAYTON, M., SIM, E. and MCQUEEN, C. A., 1999, N-acetylation of the heterocyclic amine batracylin by human liver. Drug Metabolism and Disposition, 27, 966–971.
   PubMedGoogle Scholar
• STDRMER, E., ROOTS, I. and BROCKMDLLER, J., 2000, Benzydamine n-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FM03 polymorphisms on enzyme activity. British Journal of Clinical Pharmacology, 50, 553–561.
   PubMedGoogle Scholar
• STREETMAN, D. S., BEATING, J. S., JR. and NAFZIGER, A. N., 2000, Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics, 10, 187–21 6.
   Google Scholar
• STREETMAN, D. S., BLEAKLEY, J. F., KIM, J. S., NAFZIGER, A. N., LEEDER, J. S., GAEDIGK, A., GOTSCHALL, R., KEARNS, G. L. and BEATING, J. S., 2000, Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the 'Cooperstown' cocktail. Clinical Pharmacology and Therapeutics, 68, 375–383.
   PubMed Web of Science ®Google Scholar
• SUZUKI, H., KNELLER, B., RAO, S., JONES, J., TRAGER, W. F. and RETTIE, A. E., 2000, Hydantoin and barbiturate inhibitors of CYP2C19 and CYP2C9, ISSX, Indianapolis, USA. Drug Metabolism Reviews, 32, suppl. 2.
   Google Scholar
• SWEENEY, D. J., BOUSKA, J., MACHINIST, J., BELL, R., CARTER, G., CEPA, S. and NELLANS, H. N., 1992, Glucuronidation of zileuton (A-64077) by human hepatic microsomes. Drug Metabolism and Disposition, 20, 328–329.
   PubMedGoogle Scholar
• TANAKO M., HASEGAWA, R., FUKUDA, T., YUMOTO, R., NAGAI, J. and MURAKAMI, T., 1998, Interaction with p-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. European Journal of Pharmacology, 358, 289–294.
   Google Scholar
• TASSANEEYAKUL, M. E., VERNONESE, M. E., BIRKETT, D. J., GONZALEZ, F. J. and MINERS, J. O., 1993, Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochemical Pharmacology, 46, 1975–1981.
   Google Scholar
• TASSANEEYAKUL, W., BIRKETT, D. J. and MINERS, J. O., 1998, Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica, 28, 293–301.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL, W., Guo, L. Q., FUKUDA, K., OHTA, T. and YAMAZGE, Y., 2000, Inhibition selectivity of grapefruit juice components on human cytochromes P450. Archives of Biochemistry and Biophysics, 378, 356–363.
   PubMed Web of Science ®Google Scholar
• TESTA, B. and JENNER, P., 1981, Inhibitors of cytochrome P450s and their mechanism of action. Drug Metabolism Reviews, 12, 1–117.
   PubMed Web of Science ®Google Scholar
• THUMMEL, K. E., O'SHEA, D., PAINE, M. F., SHEN, D. D., KUNZE, K. L., PERKINS, J. D. and WILKINSON, G. R., 1996, Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-medicated metabolism. Clinical Pharmacology and Therapeutics, 59, 491–503.
   Google Scholar
• THUMMEL, K. E., SHEN, D. D., CARITHERS, R. L., HARTWELL, P., PODOLL, T. D., TRAGER, W. F. and KUNZE, K. L., 1 993, Prediction of in vivo midazolam clearance from hepatic CYP3A content and midazolam 1-hydroxylation activity in liver transplant patients. ISSX Proceedings, 4, 235–230.
   Google Scholar
• THUMMEL, K. E., SHEN, D. D., PODOLL, T. D., KUNZE, K. L., TRAGER, W. F., HARTWELL, P. S., RAISYS, V. A., MARSH, C. L., McVicAR, J. P., BARR, D. M., PERKINS, J. D. and CARITHERS, JR, R. L., 1994a, Use of midazolam as a human cytochrome P450 3A probe: I. In vitro in correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549–556.
   Google Scholar
• THUMMEL, K. E., SHEN, D. D., PODOLL, T. D., KUNZE, K. L., TRAGER, W. F., HARTWELL, P. S., RAISYS, V. A., MARSH, C. L., McVicAR, J. P., BARR, D. M., PERKINS, J. D. and CARITHERS, JR, R. L., 1994b, Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and Experimental Therapeutics, 271, 557–566.
   PubMed Web of Science ®Google Scholar
• TOOLEY, A., ROSTAMI-HODJEGAN, A., LENNARD, M. S. and TUCKER, G. T., 1999, Acute inhibition of methadone metabolism by ritonavir: projection of interindividual variability from in vitro data. British Journal of Clinical Pharmacology, 48, 883p–884p.
   Google Scholar
• TUKEY, R. H. and STRASSBURG, C. P., 2000, Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annual Reviews of Pharmacology and Toxicology, 40, 581–616.
   PubMed Web of Science ®Google Scholar
• VAN ASPEREN, J., VAN TELLINGEN, O. and BEHNEN, J. H., 1998, The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacological Research, 37, 432–435.
   Google Scholar
• VERSCHRAAGEN, M., KOKS, C. H. W., SCHELLENS, J. H. M. and BEHNEN, J. H., 1999, P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacological Research, 40, 301–306.
   Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU-BIBBO, M. M., HARMATZ, J. S. and SHADER, R. I., 1994, Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23–31.
   Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S., DUAN, S. X., HARREL, L. M., COTREAU-BIBBO, M. M., PRITCHARD, G. A., WRIGHT and SHADER, R. I., 1996b, Triazolarn biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. Journal of Pharmacology and Experimental Therapeutics, 276, 370–379.
   Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., SCHMIDER, J., DUAN, S. X., WRIGHT, C. E., HARMATZ, J. S. and SHADER, R. I., 1 996a, Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. Journal of Clinical Pharmacology, 36, 783–791.
   Google Scholar
• WACHER, V. J., Wu, C. and BENET, L. Z., 1995, Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and p-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis, 13, 135–145.
   PubMedGoogle Scholar
• WANG, R. W., NEWTON, D. J., Lui, N., ATKINS, W. M. and Lu, A. Y. H., 2000, Human cytochrome P-450 3A4: in vitro drug—drug interaction patterns are substrate-dependent Drug Metabolism and Disposition, 28, 360–366.
   Google Scholar
• WARD, S. and BACK, D. J., 1993, Metabolism of gestodene in human liver cytosol and microsomes in vitro. Journal of Steroid Biochemical Molecular Biology, 46, 235–243.
   PubMedGoogle Scholar
• WATKINS, P. B., MURRAY, S. A., WINKLEMAN, L. G., HEUMAN, D. M., WRIGHTON, S. A. and GUZALIAN, P. S., 1989, Erythromycin breath-test as an assay of glucocorticoid-inducible liver cytochromes P-450: studies in rats and patients. Journal of Clinical Investigations, 83, 688–697.
   PubMed Web of Science ®Google Scholar
• WATKINS, P. B., TURGEON, D. K., SAENGER, P., LOWN, K. S., KOLARS, J. C., HAMILTON, T., FISHMAN, K., GUZELIAN, P. S. and VOORHEES, J. J., 1992, Comparison of urinary 613-cortisol and the erythromycin breath test as measures of hepatic P45011IA (CYP3A) activity. Clinical Pharmacology and Therapeutics, 52, 265–273.
   PubMed Web of Science ®Google Scholar
• WATKINS, P. B., WRIGHTON, S. A., MAUREL, P., SCHEUTZ, E. G., MENDEZ-PICON, G., PARKER, G. A. and GUZILIAN, P. S., 1985, Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences, USA, 82, 6310–6314.
   Google Scholar
• WATKINS, P. B., WRIGHTON, S. A., SciiEuTz, E. G., Motow.a, D. T. and GUZELIAN, P. S., 1987, Identification of glucocorticiod-inducible cytochrome P-450 in the intestinal mucosa in rats and man. Journal of Clinical Investigation, 80, 1029–1036.
   Google Scholar
• WEAVER, R. J., DICKINS, M. and BURKE, M. D., 1993, Cytochrome P450 2C9 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in human liver. Biochemical Pharmacology, 46, 1183–1197.
   PubMed Web of Science ®Google Scholar
• WEAVER, R. J., DICKINS, M. and BURKE, M. D., 1995, Hydroxylation of the antimalarial drug 58C80 by CYP2C9 in human liver microsomes: comparison with mephenytoin and tolbutamide hydroxylations. Biochemical Pharmacology, 49, 997–1004.
   PubMed Web of Science ®Google Scholar
• WEAVER, R. J., DICKINS, M. and BURKE, M. D., 1999, A comparison of basal and induced hepatic microsomal cytochrome P450 monooxygenase activities in the cynomologous monkey (Macaca fascicularis) and man. Xenobiotica, 29, 467–482.
   PubMed Web of Science ®Google Scholar
• WEBER, W. W., LEVY, G. N. and HEIN, D. W., 1990, Acetylation. In G. J. Mulder (ed.), Conjugation Reactions in Drug Metabolism (London: Taylor & Francis), pp. 163–191.
   Google Scholar
• WILKINSON, C. F., HETNARSKI, K., CANTWELL, G. P. and DI CARLO, F. J., 1974, Structure—activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo. Biochemical Pharmacology, 23, 2377–2386.
   PubMed Web of Science ®Google Scholar
• WOOD, M., 1991, Pharmacokinetic drug interactions in anaesthetic practice. Clinical Pharmacokinetics, 21, 285–307.
   PubMedGoogle Scholar
• WRIGHTON, S. A. and RING, B. J., 1994, Inhibition of human CYP3A catalyzed i-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharmaceutical Research, 11, 921–923.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., RING, B. J. and VANDENBRANDEN, M., 1995, The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicology Pathology, 23, 199–208.
   PubMed Web of Science ®Google Scholar
• YAMANO, K., YAMAMOTO, K., KOTAKI, H., SAWADA, Y. and IGA, T., 1999, Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Metabolism and Disposition, 27, 395–402.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, M., SUZUKI, H., HANANO, M., TOKUI, T., KOMAI, T. and SUGIYAMA, Y., 1993, Na+ - independent multispecific anion transporter mediates active transport of pravastatin into rat liver. American Journal of Physiology, 264, G36—G44.
   Google Scholar
• YASUMORI, T., NAGATA, K., YANG, S. K., CHEN, L.S., MURAYAMA, N., YAMAZOE, Y. and KATO, R., 1993, Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacoge-netics, 3, 291–301.
   PubMedGoogle Scholar
• YEATES, R. A., LAUTEN, H. and ZIMMERMAN, T., 1996, Interaction between midazolam and clarithromycin: comparison with azithromycin. International Journal of Clinical Pharmacology and Therapeutics, 34, 400–405.
   PubMedGoogle Scholar
• YEUNG, C. K., LANG, D. H., THUMMEL, K. E. and RETTIE, A. E., 2000, Immunoquantitation of FM01 in human liver, kidney, and intestine. Drug Metabolism and Disposition, 28, 1107–1111.
   PubMed Web of Science ®Google Scholar
• Yu, D. K., 1999, The contribution of p-glycoprotein to pharmacokinetics drug—drug interactions. British Journal of Clinical Pharmacology, 39, 1 203–1211.
   Google Scholar
• ZALESKI, J., BANSAL, S. K. and GESSNER, T., 1983, Formation of glucuronide, sulphate and glutathione conjugates of benzo[a]pyrene metabolites in hepatocytes isolated from inbred strains of mice. Carcinogenesis, 4, 1359–1366.
   PubMed Web of Science ®Google Scholar
• ZAND, R., SIDNEY, N., SLATTERY, J., THUMMEL, K., KALHORN, T., ADAMS, S. and WRIGHT, J., 1993, Inhibition and induction of cytochrome P4502E1- catalyzed oxidation by isoniazid in humans. Clinical Pharmacology and Therapeutics, 54, 142–149.
   PubMed Web of Science ®Google Scholar
• ZHANG, Q., DUNBAR, D., OSTROWSKA, A., ZEISLOFT, S., YANG, J. and KAMINSKY, L. S., 1999, Characterization of human small intestinal cytochromes P-450. Drug Metabolism and Disposition, 27, 804–809.
   PubMed Web of Science ®Google Scholar
• ZHANG, Y., BLOUIN, R. A., MCNAMARA, P. J., STEINMETZ, J. and WEDLUND, P. J., 1991, Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. British Journal of Clinical Pharmacology, 31, 350–352.
   PubMedGoogle Scholar
• ZIELGER, D. M., 1991, Mechanisms, multiple forms and substrate specificities of fiavin- containing mono-oxygenases. In N-oxidation of drugs, P. Hlavica and L. A. Damani (eds) (London: Chapman & Hall), pp. 59–70.
   Google Scholar